Trials / Unknown
UnknownNCT05278832
A Study of QLS31905 in Patients With Advanced Solid Tumors
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of QLS31905 in Patients With Claudin18.2-positive Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLS31905 | QLS31905 injection |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
- First posted
- 2022-03-14
- Last updated
- 2022-03-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05278832. Inclusion in this directory is not an endorsement.